Med. praxi. 2014;11(4):143-146

Treatment of arterial hypertension in patient with metabolic syndrome

prof.MUDr.Martin Haluzík, DrSc.
III. interní klinika 1. LF UK a VFN, Praha

Metabolic syndrome is defined as a combination of obesity, arterial hypertension, dyslipidemia, impaired glucose metabolism and other

pathologies that in combination markedly increase cardiovascular risk. The treatment of arterial hypertension in patient with metabolic

syndrome is an important part of complex lifestyle and therapeutic measures aiming at lowering total cardiovascular risk. Increased

physical activity, hypocaloric diet with sodium restriction and smoking cessation represent an integral part of lifystele measures. Pharmacological

treatment of choice are ACE-inhibitors or AT1-receptor blockers in combination with calcium channel blockers combined with

other antihypertensive agents such as diuretics, beta-blockers and others, if necessary. Intensive treatment of diabetes, dyslipidemia

and the intervention of other cardiovascular risk factors is another important part of complex therapeutic approach.

Keywords: arterial hypertension, metabolic syndrome, insulin resistance, ACE inhibitors, AT1-receptor blockers

Published: June 1, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Haluzík M. Treatment of arterial hypertension in patient with metabolic syndrome. Med. praxi. 2014;11(4):143-146.
Download citation

References

  1. O'Rahilly S. Science, medicine, and the future. Non-insulin dependent diabetes mellitus: the gathering storm. BMJ 1997; 314: 955-959. Go to original source... Go to PubMed...
  2. Reaven G. Metabolic syndrome: pathophysiology and implications for management of cardiovascular disease. Circulation 2002; 106: 286-268. Go to original source... Go to PubMed...
  3. Svačina S, Owen K. Syndrom inzulínové rezistence. Praha: Triton 2003.
  4. Ravussin E, Smith SR. Increased fat intake, impaired fat oxidation, and failure of fat cell proliferation result in ectopic fat storage, insulin resistance, and type 2 diabetes mellitus. Ann N Y Acad Sci 2002; 967: 363-378. Go to original source... Go to PubMed...
  5. Boden G, Shulman GI. Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction. European journal of clinical investigation 2002; 32(Suppl 3): 14-23. Go to original source... Go to PubMed...
  6. Bluher M. Adipose tissue dysfunction contributes to obesity related metabolic diseases. Best practice & research 2013; 27: 163-177. Go to original source... Go to PubMed...
  7. Dolinkova M, Dostalova I, Lacinova Z, et al. The endocrine profile of subcutaneous and visceral adipose tissue of obese patients. Molecular and cellular endocrinology 2008; 291: 63-70. Go to original source... Go to PubMed...
  8. Rosolova H. Sympatický nervivý systém a inzulínová rezistence. Vnitřní lékařstvíl 2003; 49: 61-65.
  9. Filipovský J, Widimský JJ, Ceral J, et al. Diagnostické a léčebné postupy u arteriální hypertenze - verze 2012. Doporučení České společnosti pro hypertenzi. Vnitřní lékařství 2012; 58: 785-801. Go to PubMed...
  10. Škrha J, et al. Diabetologie. 1. vydání ed. Praha: Galén 2009.
  11. Češka R. Cholesterol a ateroskleróza: léčba hyperlipidémií. Praha: Maxdorf 1999.
  12. Scheen AJ. Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system. Drugs 2004; 64: 2537-2565. Go to original source... Go to PubMed...




Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.